Prostate cancer | Editor-in-chief: Amit Bahl

Diagnosing clinically significant PCa

Background

Diagnosing PCa should focus on detecting clinically significant PCa. Insignificant tumours are preferably not found, since there is a strong link between overdetection and overtreatment that is very hard to break.

Educational Objective

Aim of this course is to provide insight into the most appropriate diagnostic options for distinct patient profiles.

Specialty

Urology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Adverse pathology at radical prostatectomy

Background

Patients who present with adverse pathology at RP + extended pelvic lymph node extension (ePLND) are at higher risk of recurrence. The most appropriate therapy for these patients differs according to the type and number of adverse features.

Educational Objective

Aim of this course is to provide insights into the most appropriate treatment of patients presenting with adverse pathology at RP + ePLND.

Specialty

Urology, Radiation oncology, Medical oncology

Target Audience

CME (basic), Residents (senior)

Latest update

May 2019

Biochemical recurrence after radical prostatectomy

Background

Biochemical recurrence (BCR) occurs in a significant proportion of patients who received primary curative treatment for localised PCa. Multiple clinical factors must be taken into account to optimally treat a patient with N0 M0 PSA-recurrent PCa.

Educational Objective

Aim of this course is to provide insights into the most appropriate treatment options of men presenting with BCR after radical prostatectomy (RP).

Specialty

Urology, Radiation oncology, Medical oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Radical treatment of low- and intermediate-risk PCa

Background

Men with PSA-detected clinically localised PCa have excellent 10-year survival rates irrespective of the treatment (ProtecT trial). Is treatment choice here just a matter of patient preference?

Educational Objective

Gain insight into the treatment choices for men with low- and intermediate-risk PCa, with a focus on radical treatments.

Specialty

Urology, Radiation oncology

Target Audience

CME (basic), Residents (senior)

Latest update

July 2019

Active surveillance: yes or no?

Background

Overdiagnosis of indolent PCa still is prevalent due to PSA testing and often leads to overtreatment. A lot of men eligible for active surveillance according to international guidelines do receive radical therapy.

Educational Objective

The aim is to assess if a patient is a good candidate for active surveillance or not.

Specialty

Urology, Radiation oncology

Target Audience

CME (basic), Residents (senior)

Latest update

June, 2019

Treatment decision-making in castration-resistant prostate cancer

Background

The optimal treatment choice/sequence for an individual CRPC patient is challenging. This topic is limited to patients with a castrate testosterone level. Bone-protective agents fall beyond the scope of this topic.

Educational Objective

Gain insight into the appropriate selection of life-prolonging treatments for non-metastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC).

Specialty

Urology, medical oncology

Target Audience

CME (basic, intermediate), Residents (senior)

Latest update

July 1, 2019

New data, new treatment recommendations in metastatic hormone-sensitive PCa

Background

New evidence on treatment options for patients with mHSPC is paving the way for a more personalised treatment approach.

Educational Objective

Learn how new clinical data influences the treatment choice in patients with mHPSC: which patients benefit from systemic combination treatment; which patients can benefit from radiotherapy?

Specialty

Urology, medical oncology

Target Audience

CME (intermediate-advanced), Residents (senior)

Latest update

April 2019

--NEW-- Oligometastatic PCa: treating the primary and/or metastases

Background

Oligometastatic prostate cancer (OMPC) is a heterogeneous disease state which is poorly understood and of which the clinical implications are unclear. In this topic, the location of the metastases does not rule out metastasis-directed therapy.

Educational Objective

Gain insight into the factors deciding on local therapy of the primary and metastasis-directed therapy.

Specialty

Urology, medical oncology, radiation oncology

Target Audience

CME (intermediate-advanced) Residents (senior)

Latest update

June 2019

--NEW-- ADT resource management: finding the right ADT for the right patient

Background

Androgen deprivation therapy (ADT) has been the standard of care in metastatic prostate cancer. Several ways exist to achieve androgen deprivation, each with its own drawbacks and benefits.

Educational Objective

Gain insight in the different options of androgen deprivation therapy and how to select the most appropriate option for your particular patient.

Specialty

Urology, medical oncology, radiation oncology

Target Audience

CME (basic-intermediate), Residents (senior)

Latest update

June 2019

--NEW-- Treatment of high-risk PCa: the basics

Background

Most patients with high-risk prostate cancer (PCa) will need a multimodal treatment approach, combining different modalities such as radical prostatectomy (RP), radiation therapy (RT), and androgen deprivation therapy (ADT).

Educational Objective

This course aims to provide basic insights into the most appropriate 1st-line treatment options for patients with high-risk PCa.

Specialty

Urology - Radiation oncology - Medical oncology

Target Audience

CME: basic - Residents: senior

Latest update

July 2019

--NEW-- High-risk non-metastatic prostate cancer: the devil is in the details

Background

Most patients with high-risk prostate cancer (PCa) will need a multimodal treatment approach. However, not all high-risk patients are at the same risk of disease progression or death.

Educational Objective

To provide insight into factors determining treatment appropriateness in high-risk non-metastatic PCa. To clarify if there a role for systemic therapy in clinical practice for this patient population.

Specialty

Urology, medical oncology, radiation oncology

Target Audience

CME: intermediate-advanced | Residents: senior

Latest update

July 2019